Arana-Luna LL, Álvarez-Vera JL, de la Peña-Celaya JA, Mena-Zepeda V, Ortiz-Zepeda M, Espitia-Ríos ME, Pérez Zúñiga JM, Alvarado-Ibarra M

Language: Spanish
References: 25
Page: 32-37
PDF size: 153.98 Kb.

ABSTRACT

Introduction: In Mexico, seroprevalence of Entamoeba histolytica is 8.4%. The intestinal amebiasis in patients with acute leukemia of novo, after the start of chemotherapy (CT) in the Hematology Service of the CMN 20 de Noviembre is 12%, even if patients show a negative baseline coprological test. Objective: To find out if the administration of tinidazole, in patients with acute leukemia and negative coprological test, at the beginning of the CT, decreases the incidence of amoebic colitis during the induction to remission. Method: Prospective and not comparative study. Patients with de novo diagnosis of acute leukemia who initiate induction and initial coprological CT. Tinidazole was indicated, 2 g/day for 5 days in the first week of CT started. They were monitored until the induction was concluded and hematopoietic recovery started. Results: 38 patients, 15 women and 23 men with a mean age of 44 years (16-72), with acute lymphoblastic leukemia 19, myeloblastic 16 and promyelocytic 3. Cases without and with intestinal amebiasis were 35 and 3, respectively. Patients with amebiasis only received tinidazole for 3 days and it was given 2 days after the CT started. Conclusion: Tinidazole, in patients with acute de novo leukemia who initiate induction CT, is effective in the prevention of intestinal amebiasis, during the induction stage, if administered at 2 g/day, for five days, starting on day 1 of the CT.

REFERENCES

1. Trevino Garcia-Manzo N, Escandon-Romero C, Escobedo de la Pena J, Hernandez-Ramos JM, Fierro-Hernandez H. Amebiasis in the epidemiologic transition in Mexico: its morbidity and mortality trends in the Mexican Institute of Social Security. Arch Med Res. 1994;25:393-9.

2. Mortimer L, Chadee K. The immunopathogenesis of Entamoeba histolytica. Exp Parasitol. 2010;126:366-80.

3. Stanley SL Jr. Amoebiasis. Lancet. 2003;361:1025-34.

4. Cornick S, Tawiah A, Chadee K. Roles and regulation of the mucus barrier in the gut. Tissue barriers. 2015;3 e982426.

5. Stanley SL Jr. Protective immunity to amebiasis: new insights and new challenges. J Infect Dis. 2001;184:504-6.

6. Caballero-Salcedo A, Viveros-Rogel M, Salvatierra B, Tapia-Conyer R, Sepulveda-Amor J, Gutierrez G, et al. Seroepidemiology of amebiasis in Mexico. Am J Trop Med Hyg. 1994;50:412-9.

7. Haque R, Huston CD, Hughes M, Houpt E, Petri WA. Amebiasis. 2003;348:1565-73.

8. Petri WA Jr, Singh U. Diagnosis and management of amebiasis. Clin Infect Dis. 1999;29:1117-25.

9. Ximenez C, Cerritos R, Rojas L, Dolabella S, Moran P, Shibayama M, et al. Human amebiasis: breaking the paradigm? Int J Environ Res Public Health. 2010;7:1105-20.

10. Baxt LA, Singh U. New insights into Entamoeba histolytica pathogenesis. Curr Opin Infect Dis. 2008;21:489-94.

11. Bercu TE, Petri WA, Behm BW. Amebic colitis: New insights into pathogenesis and treatment. Curr Gastroenterol Rep. 2007;9:429-33.

12. Wilson IW, Weedall GD, Hall N. Host-parasite interactions in Entamoeba histolytica and Entamoeba dispar: what have we learned from their genomes? Parasite Immunol. 2012;34:90-9.

13. Morf L, Singh U. Entamoeba histolytica: a snapshot of current research and methods for genetic analysis. Curr Opin Microbiol. 2012;15:469-75.

14. Tanyuksel M, Petri WA, Jr. Laboratory diagnosis of amebiasis. Clin Microbiol Rev. 2003;16:713-29.

15. Skappak C, Akierman S, Belga S, Novak K, Chadee K, Urbanski SJ, et al. Invasive amoebiasis: a review of Entamoeba infections highlighted with case reports. Can J Gastroenterol Hepatol. 2014;28:355-9.

16. Baden LR, Swaminathan S, Angarone M, Blouin G, Camins BC, Casper C, et al. Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN. 2016; 14:882-913.

17. Bernin H, Marggraff C, Jacobs T, Brattig N, Le VA, Blessmann J, et al. Immune markers characteristic for asymptomatically infected and diseased Entamoeba histolytica individuals and their relation to sex. BMC infectious diseases. 2014;14:621.

18. Keefe DM. Intestinal mucositis: mechanisms and management. Current opinion in oncology. 2007;19:323-7.

19. Castellanos Galan JE. Amebiasis intestinal en pacientes con leucemia aguda de novo. CMN 20 de Noviembre ISSSTE. UNAM, 2001.

20. Fotedar R, Stark D, Beebe N, Marriott D, Ellis J, Harkness J. Laboratory diagnostic techniques for Entamoeba species. Clinical microbiology reviews. 2007;20 511-32.

21. Singh A, Houpt E, Petri WA. Rapid diagnosis of intestinal parasitic protozoa, with a focus on Entamoeba histolytica. Interdisciplinary perspectives on infectious diseases 2009;2009:547090.

22. Dans LF, Martínez EG. Amoebic dysentery. BMJ clinical evidence. 2007; 2007:918.

23. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2011;52:e56-93.

24. Guerrant RL, Osterholm MT, Bennish ML, Pickering LK, Slutsker L, Griffin PM, et al. Practice guidelines for the management of infectious diarrhea. Clinical Infectious Diseases. 2001;32:331-51.

25. Davila ML. Neutropenic enterocolitis. Current opinion in gastroenterology. 2006;22:44-7.